Relationships between antithrombin activity, anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass

Perfusion

Volumn 26, Issue 6, 2011, Pages 487-495

  Muedra, V ^a   Bonanad, S ^b   Gomez M ^a   Villalonga, V ^b   Sanchez F ^a   Llopis, J E ^a  

^a Department of Anesthesia Critical Care and Pain Therapy   (Spain)

^b NONE   (Spain)

Author keywords

antithrombin; cardiopulmonary bypass; extracorporeal circulation; heparin resistance

Indexed keywords

HEPARIN;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; ATELECTASIS; BLOOD CLOTTING; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CEREBROVASCULAR ACCIDENT; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; FORWARD HEART FAILURE; GROUPS BY AGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART SURGERY; HEART VENTRICLE ARRHYTHMIA; HEMATOLOGICAL PARAMETERS; HEMATOTHORAX; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PNEUMONIA; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME;

AGED; ANTICOAGULANTS; ANTITHROMBIN III; ANTITHROMBINS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; WHOLE BLOOD COAGULATION TIME;

EID: 80155172594     PISSN: 02676591     EISSN: 1477111X     Source Type: Journal    
DOI: 10.1177/0267659111412999     Document Type: Article

References (38)

1. Gettins PG. Serpin structure, mechanism, and function. Chem Rev. 2002 ; 102 (12). 4751-804
2. Björk I, Olson S Chemistry and biology of serpins. Church F Cunningham D Ginsburg D Hoffman M Stone S Tollefsen D, ed. New York, NY: Plenum Press ; 1997: 17-22.
3. Grossmann R, Babin-Ebell J, Misoph M, et al. Changes in coagulation and fibrinolytic parameters caused by extracorporeal circulation. Heart Vessels. 1996 ; 11 (6). 310-317 (Pubitemid 27298206)
4. Ranucci M, Ditta A, Boncilli A, et al. Determinants of antithrombin consumption in cardiac operations requiring cardiopulmonary bypass. Perfusion. 2004 ; 19 (1). 47-52 (Pubitemid 38386649)
5. Ranucci M, Frigiola A, Menicanti L, Ditta A, Boncilli A, Brozzi S. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med. 2005 ; 33 (2). 355-360 (Pubitemid 40216549)
6. Levy JH, Sniecinski RM. Activated clotting times, heparin responses, and antithrombin: have we been wrong all these years?. Anesth Analg. 2010 ; 111 (4). 833-835
7. Staples MH, Dunton RF, Karlson KJ, Leonardi HK, Berger RL. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg. 1994 ; 57 (5). 1211-1216 (Pubitemid 24204506)
8. Avidan MS, Levy JH, van Aken H, et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005 ; 130 (1). 107-113 (Pubitemid 40941676)
9. Lemmer JH, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2002 ; 123 (2). 213-217 (Pubitemid 34127106)
10. Kanbak M. The treatment of heparin resistance with antithrombin III in cardiac surgery. Can J Anaesth. 1999 ; 46 (6). 581-585 (Pubitemid 29327686)
11. Rossi M, Ranucci M, Soro G, Schiavello R, Guarneri S. Purified antithrombin supplementation in coronary revascularisation operations. Eur J Anaesthesiol. 2007 ; 24 (Suppl 40). 71-76 (Pubitemid 47066008)
12. Ranucci M, Isgro G, Cazzaniga A, Soro G, Menicanti L, Frigiola A. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion. 1999 ; 14 (6). 437-442 (Pubitemid 29537489)
13. Paparella D, Cappabianca G, Scrascia G, et al. Antithrombin after cardiac surgery: implications on short and mid-term outcome. J Thromb Thrombolysis. 2009 ; 27 (1). 105-114
14. Spiess BD. The relationship between coagulation, inflammation and endothelium - a pyramid towards outcomes. Lippincott Williams & Wilkins, Baltimore. 2000: ;: 190-196
15. Chandler WL. Effects of hemodilution, blood loss, and consumption on hemostatic factor levels during cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2005 ; 19 (4). 459-467 (Pubitemid 41112182)
16. Ranucci M, Conti D, Castelvecchio S, et al. Hematocrit on cardiopulmonary bypass and outcome after coronary surgery in nontransfused patients. Ann Thorac Surg. 2010 ; 89 (1). 11-17
17. Engstrom KG, Appelblad M, Brorsson B. Mechanisms behind operating room blood transfusions in coronary artery bypass graft surgery patients with insignificant bleeding. J Cardiothorac Vasc Anesth. 2002 ; 16 (5). 539-544 (Pubitemid 35155264)
18. Taneja R, Fernandes P, Marwaha G, Cheng D, Bainbridge D. Perioperative coagulation management and blood conservation in cardiac surgery: a Canadian survey. J Cardiothorac Vasc Anesth. 2008 ; 22 (5). 662-669
19. Basora M, Fita G, Panigua P, Litvan H, Flo A, Reverter JC. Survey of perioperative hemostasis and transfusion management in cardiac surgery: how do anesthesiologists practice? (in Spanish). Rev Esp Anestesiol Reanim. 2010 ; 57 (1). 3-10
20. Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 1993 ; 70 (3). 380-385 (Pubitemid 23254660)
21. Wendel HP, Eckstein FS, Fink E, et al. Increased coagulation and bradykinin release in shed pleural blood during cardiac surgery. Immunopharmacology. 1999 ; 44 (1-2). 119-122
22. Salis S, Mazzanti VV, Merli G, et al. Cardiopulmonary bypass duration is an independent predictor of morbidity and mortality after cardiac surgery. J Cardiothorac Vasc Anesth. 2008 ; 22 (6). 814-822
23. Avidan MS, Levy JH, Scholz J, et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiol. 2005 ; 102 (2). 276-284 (Pubitemid 40189074)
24. Dietrich W, Spannagl M, Schramm W, Vogt W, Barankay A, Richter JA. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1991 ; 102 (4). 505-514
25. Linden MD, Schneider M, Baker S, Erber WN. Decreased concentration of antithrombin after preoperative therapeutic heparin does not cause heparin resistance during cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2004 ; 18 (2). 131-135 (Pubitemid 38506855)
26. Chan T, Hwang NC, Lim CH. A statistical analysis of factors predisposing patients to heparin resistance. Perfusion. 2006 ; 21 (2). 99-103
27. Ranucci M, Isgro G, Cazzaniga A, et al. Different patterns of heparin resistance: therapeutic implications. Perfusion. 2002 ; 17 (3). 199-204 (Pubitemid 34467126)
28. Spiess BD. Treating heparin resistance with antithrombin or fresh frozen plasma. Ann Thorac Surg. 2008 ; 85 (6). 2153-2160 (Pubitemid 351685591)
29. Garvin S, Muehlschlegel JD, Perry TE, et al. Postoperative activity, but not preoperative activity, of antithrombin is associated with major adverse cardiac events after coronary artery bypass graft surgery. Anesth Analg. 2010 ; 111 (4). 862-869
30. Slight RD, Buell R, Nzewi OC, McClelland DB, Mankad PS. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2008 ; 22 (1). 47-52 (Pubitemid 351187885)
31. Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg. 1994 ; 108 (6). 1076-1082 (Pubitemid 24379861)
32. Hardy JF, Belisle S, Robitaille D, Perrault J, Roy M, Gagnon L. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg. 1996 ; 112 (1). 154-161 (Pubitemid 26268982)
33. Garvin S, Fitzgerald DC, Despotis G, Shekar P, Body SC. Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesth Analg. 2010 ; 111 (4). 849-855
34. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg. 1975 ; 69 (5). 674-684
35. Garvin S, Fitzgerald D, Muehlschlegel JD, et al. Heparin dose response is independent of perioperative antithrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations. Anesth Analg. 2010 ; 111 (4). 856-861
36. Ranucci M. Perioperative haemostasis and coagulation management in cardiac surgery: a European survey. Eur J Anaesthesiol. 2007 ; 24 (Suppl 40). 1-13 (Pubitemid 47066002)
37. Koster A, Chew D, Kuebler W, Habazettl H, Hetzer R, Kuppe H. High antithrombin III levels attenuate hemostatic activation and leukocyte activation during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2003 ; 126 (3). 906-907 (Pubitemid 37152002)
38. Szefner J. Preventing and managing postoperative bleeding in cardiac surgery by controlling disseminated intravascular coagulation. Eur J Anaesthesiol. 2007 ; 24 (suppl 40). 59-66 (Pubitemid 47066009)